Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE       Parliamentary submission
DATE              2017-08-18
TOPICS            Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE        2017-06-28
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents

---

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE        2017-05-26
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the Senate Standing Committee on Social Affairs, Science and Technology

April 7, 2017

CMA Policybase - Canadian Medical Association
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE
Response to consultation

DATE
2017-04-05

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

April 5, 2017

CONSULTATION ON THE FEDERAL TOBACCO CONTROL STRATEGY

Dear [Name],

I am writing to you regarding the consultation on the renewal of the Federal Tobacco Control Strategy (FTCS) and wish to briefly summarize the contents of the CMA's position statement. The CMA believes a comprehensive approach is necessary for the elimination of tobacco use in Canada. The position statement recognizes the importance of addressing public health issues related to tobacco, including the need for policies that promote healthy living.

The consultation is an opportunity for all stakeholders to contribute their perspectives on the need for a renewed Federal Tobacco Control Strategy. The CMA encourages all those interested in tobacco control to participate in the consultation.

Yours sincerely,

[Your Name]

Canadian Medical Association
Position statement on prescription drug shortages in Canada

https://policybase.cma.ca/link/policy10756

POLICY TYPE          Policy document
LAST REVIEWED       2017-03-04
DATE                2013-05-25
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE
Parliamentary submission

DATE
2016-10-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE Response to consultation
DATE 2016-08-29
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Cher(e) Isabelle: application d’herboriste

DACA, September 8, 2016 – The CMA’s submission to the Task Force on Marijuana Legalization and Regulation expresses concern for the health and well-being of all Canadians, particularly those affected by health problems.

We propose to provide legal access to cannabis products in a manner that respects the high standards of health and safety for the public. This will ensure that products are accessible only to adults over the age of 18 and that the health and safety of all Canadians are protected. We also recommend that the federal government regulate and limit the availability of cannabis products to ensure their safety and accessibility to the public.

As your task force considers the potential implications of cannabis legalization, it is important to note that the health and safety of all Canadians must be considered. Therefore, we urge the government to adopt a comprehensive approach to cannabis legalization that prioritizes the health and well-being of all Canadians.

The CMA recommends that the federal government adopt a comprehensive approach to cannabis legalization.

1. Establishing a regulatory framework
2. Ensuring the health and safety of all Canadians
3. Limiting the availability of cannabis products
4. Providing education and support

We believe that a comprehensive approach to cannabis legalization will ensure the health and safety of all Canadians.

For further information, please contact:

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  
Response to consultation

DATE  
2016-08-12

TOPICS  
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016

Dear [Name],

I am writing to you on behalf of the Canadian Medical Association (CMA). We are writing in response to Health Canada’s Consultation on “Plain and Standardized Packaging.”

The CMA supports the move towards plain and standardized packaging for prescription drugs and cannabis products. We believe that this will help to reduce the incidence of drug misuse and addiction, as well as make it easier for patients to identify their medications.

We are concerned, however, that the proposed changes to the packaging of pharmaceuticals may have unintended consequences. For example, the use of symbols or colors to indicate different types of medications may lead to confusion among patients.

We also believe that the proposed changes to the packaging of cannabis products may have unintended consequences. For example, the use of symbols or colors to indicate different types of cannabis products may lead to confusion among patients.

We urge Health Canada to consider the potential unintended consequences of the proposed changes to the packaging of pharmaceuticals and cannabis products.

Sincerely,

[Your Name]

Canadian Medical Association
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE  Response to consultation
DATE  2016-03-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2016-01-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Health care and patient safety</td>
</tr>
</tbody>
</table>

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE  Response to consultation
DATE         2015-06-08
TOPICS       Pharmaceuticals, prescribing, cannabis, drugs

Documents
Complementary and alternative medicine (update 2015)
https://policybase.cma.ca/link/policy11529

POLICY TYPE
Policy document

DATE
2015-05-30

REPLACES
Complementary and alternative medicine (Update 2008)

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535

POLICY TYPE  Policy document
DATE       2015-05-30
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE Parliamentary submission
DATE 2014-10-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents